Literature DB >> 31662861

Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study.

David Marti-Aguado1, María Pilar Ballester1, Joan Tosca1, Marta Maia Bosca-Watts1, Pablo Navarro1, Rosario Anton1, Isabel Pascual1,2, Francisco Mora1,2, Miguel Minguez1,2.   

Abstract

Background: Knowing patients' ulcerative colitis history is essential to selecting the appropriate therapy according to risk stratification. Objective: To evaluate and identify predictive factors of non-response to aminosalicylates judged as the need for a step-up approach over time.
Methods: A case-control study of ulcerative colitis patients treated with aminosalicylates after the diagnosis of disease flare included in the ENEIDA single-centre registry from 1997 to 2017. Long-term treatment maintenance with aminosalicylates and higher therapeutic requirements were recorded. The cumulative incidence of treatment escalation was estimated using Kaplan-Meier curves and compared by the log-rank test. Cox regression analysis was performed to identify predictive factors of treatment with immunomodulators, biological agents or surgery.
Results: A total of 457 patients were included, of whom 28% (n = 126) were non-responders to aminosalicylates. The cumulative probability for a step-up approach within 20 years of follow up was 35%, mainly due to steroid-dependent colitis. Risk factors for treatment escalation were age ≤27 years (hazard ratio 2.31, 95% confidence interval 1.36-3.92), extensive colitis (hazard ratio 1.65, 95% confidence interval 1.04-2.60), Mayo endoscopic subscore ≥2 (hazard ratio 1.45, 95% confidence interval 1.02-2.06) and extraintestinal manifestations (hazard ratio 2.04, 95% confidence interval 1.03-4.05). Conclusions: Aminosalicylates represent an effective maintenance therapy. Younger age, extensive colitis, endoscopic disease severity and extraintestinal manifestations are risk factors for higher therapeutic requirements. © Author(s) 2019.

Entities:  

Keywords:  Colitis; aminosalicylic acids; treatment outcome; ulcerative

Mesh:

Substances:

Year:  2019        PMID: 31662861      PMCID: PMC6794696          DOI: 10.1177/2050640619854277

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  29 in total

1.  Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids.

Authors:  Esther Garcia-Planella; Míriam Mañosa; Manuel Van Domselaar; Jordi Gordillo; Yamile Zabana; Eduard Cabré; Antonio López San Román; Eugeni Domènech
Journal:  Dig Liver Dis       Date:  2011-11-11       Impact factor: 4.088

2.  Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids.

Authors:  C Bello; J Belaiche; E Louis; C Reenaers
Journal:  J Crohns Colitis       Date:  2011-02-10       Impact factor: 9.071

3.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

Review 4.  Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.

Authors:  Alexander C Ford; Jean-Paul Achkar; Khurram J Khan; Sunanda V Kane; Nicholas J Talley; John K Marshall; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2011-03-15       Impact factor: 10.864

5.  Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia.

Authors:  Siew C Ng; Zhirong Zeng; Ola Niewiadomski; Whitney Tang; Sally Bell; Michael A Kamm; Pinjin Hu; H Janaka de Silva; Madunil A Niriella; W S A A Yasith Udara; David Ong; Khoon Lin Ling; Choon Jin Ooi; Ida Hilmi; Khean Lee Goh; Qin Ouyang; Yu Fang Wang; Kaichun Wu; Xin Wang; Pises Pisespongsa; Sathaporn Manatsathit; Satimai Aniwan; Julajak Limsrivilai; Jeffri Gunawan; Marcellus Simadibrata; Murdani Abdullah; Steve W C Tsang; Fu Hang Lo; Aric J Hui; Chung Mo Chow; Hon Ho Yu; Mo Fong Li; Ka Kei Ng; Jessica Y L Ching; Victor Chan; Justin C Y Wu; Francis K L Chan; Minhu Chen; Joseph J Y Sung
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

6.  Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study.

Authors:  A Lau; N Chande; T Ponich; J C Gregor
Journal:  Aliment Pharmacol Ther       Date:  2008-06-28       Impact factor: 8.171

Review 7.  Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis.

Authors:  N To; A C Ford; D J Gracie
Journal:  Aliment Pharmacol Ther       Date:  2016-05-18       Impact factor: 8.171

8.  Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease.

Authors:  Zsuzsanna Vegh; Zsuzsanna Kurti; Lorant Gonczi; Petra Anna Golovics; Barbara Dorottya Lovasz; Istvan Szita; Mihaly Balogh; Tunde Pandur; Stephan R Vavricka; Gerhard Rogler; Laszlo Lakatos; Peter Laszlo Lakatos
Journal:  Scand J Gastroenterol       Date:  2016-02-16       Impact factor: 2.423

9.  Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis.

Authors:  Sunil Samuel; Steven B Ingle; Shamina Dhillon; Siddhant Yadav; W Scott Harmsen; Alan R Zinsmeister; William J Tremaine; William J Sandborn; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

10.  Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.

Authors:  Johan Burisch; Konstantinos H Katsanos; Dimitrios K Christodoulou; Luisa Barros; Fernando Magro; Natalia Pedersen; Jens Kjeldsen; Zsuzsanna Vegh; Peter L Lakatos; Carl Eriksson; Jonas Halfvarson; Mathurin Fumery; Corinne Gower-Rousseau; Marko Brinar; Silvija Cukovic-Cavka; Inna Nikulina; Elena Belousova; Sally Myers; Shaji Sebastian; Gediminas Kiudelis; Limas Kupcinskas; Doron Schwartz; Selwyn Odes; Ioannis P Kaimakliotis; Daniela Valpiani; Renata D'Incà; Riina Salupere; Stefania Chetcuti Zammit; Pierre Ellul; Dana Duricova; Martin Bortlik; Adrian Goldis; Hendrika Adriana Linda Kievit; Alina Toca; Svetlana Turcan; Jóngerð Midjord; Kári Rubek Nielsen; Karina Winther Andersen; Vibeke Andersen; Ravi Misra; Naila Arebi; Pia Oksanen; Pekka Collin; Luisa de Castro; Vicent Hernandez; Ebbe Langholz; Pia Munkholm
Journal:  J Crohns Colitis       Date:  2019-02-01       Impact factor: 9.071

View more
  1 in total

1.  Moving from efficacy to effectiveness: budesonide multimatrix in ulcerative colitis.

Authors:  Fernando Magro; Maria Manuela Estevinho
Journal:  United European Gastroenterol J       Date:  2019-09-22       Impact factor: 4.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.